|
|
 |
|
Total Number of Holdings (excluding cash): 50
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
297,116 |
$78,088,027.12 |
7.46% |
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
65,864 |
$75,272,672.40 |
7.19% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
515,611 |
$74,402,667.30 |
7.11% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
2,676,971 |
$74,419,793.80 |
7.11% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
286,578 |
$73,372,565.34 |
7.01% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
2,307,287 |
$40,608,251.20 |
3.88% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
175,830 |
$38,661,500.40 |
3.69% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
260,308 |
$37,676,979.92 |
3.60% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
66,257 |
$35,891,416.90 |
3.43% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
88,614 |
$35,714,986.56 |
3.41% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
305,699 |
$35,247,094.70 |
3.37% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
69,957 |
$35,309,396.61 |
3.37% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
47,671 |
$35,047,719.20 |
3.35% |
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
570,174 |
$34,866,140.10 |
3.33% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
494,077 |
$34,432,226.13 |
3.29% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
121,105 |
$28,540,815.35 |
2.73% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
424,333 |
$24,776,803.87 |
2.37% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
87,980 |
$24,022,059.20 |
2.30% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
152,933 |
$16,801,219.38 |
1.61% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
26,245 |
$15,733,090.15 |
1.50% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
90,007 |
$12,887,202.26 |
1.23% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
223,082 |
$12,755,828.76 |
1.22% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
546,432 |
$12,098,004.48 |
1.16% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
54,565 |
$11,989,021.80 |
1.15% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
36,852 |
$10,694,081.88 |
1.02% |
| Iovance Biotherapeutics, Inc. |
IOVA |
462260100 |
Biotechnology |
648,101 |
$9,212,755.72 |
0.88% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
84,787 |
$7,927,584.50 |
0.76% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
37,730 |
$7,169,077.30 |
0.69% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
38,093 |
$7,187,006.31 |
0.69% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
303,091 |
$6,152,747.30 |
0.59% |
| Adaptive Biotechnologies Corporation |
ADPT |
00650F109 |
Biotechnology |
212,478 |
$6,023,751.30 |
0.58% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
33,297 |
$5,920,206.60 |
0.57% |
| Caris Life Sciences, Inc. |
CAI |
142152107 |
Biotechnology |
207,728 |
$5,878,702.40 |
0.56% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
18,638 |
$5,646,568.48 |
0.54% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
59,275 |
$5,523,837.25 |
0.53% |
| Corcept Therapeutics Inc. |
CORT |
218352102 |
Pharmaceuticals |
46,713 |
$5,429,451.99 |
0.52% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
152,857 |
$5,460,052.04 |
0.52% |
| Tango Therapeutics, Inc. |
TNGX |
87583X109 |
Biotechnology |
231,829 |
$5,387,705.96 |
0.51% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
97,514 |
$5,294,035.06 |
0.51% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
35,837 |
$5,019,330.22 |
0.48% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
44,566 |
$4,785,942.74 |
0.46% |
| Oruka Therapeutics, Inc. |
ORKA |
687604108 |
Biotechnology |
57,169 |
$4,831,923.88 |
0.46% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
112,683 |
$4,704,515.25 |
0.45% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
14,734 |
$4,748,473.52 |
0.45% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
79,888 |
$4,548,023.84 |
0.43% |
| Dianthus Therapeutics, Inc. |
DNTH |
252828108 |
Biotechnology |
50,138 |
$4,422,672.98 |
0.42% |
| Enliven Therapeutics Inc. |
ELVN |
29337E102 |
Biotechnology |
91,465 |
$4,296,111.05 |
0.41% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
64,267 |
$4,125,298.73 |
0.39% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
183,153 |
$3,653,902.35 |
0.35% |
| Liquidia Technologies, Inc. |
LQDA |
53635D202 |
Biotechnology |
77,673 |
$2,224,554.72 |
0.21% |
| US Dollar |
$USD |
|
Other |
1,521,065 |
$1,521,065.20 |
0.15% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|